---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-024392"
form_type: "8-K"
ticker: "DMAA"
cik: "0002028614"
company_name: "Drugs Made In America Acquisition Corp."
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T19:04:30.772060+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CEO Lynn Stockwell resigns after affiliate fund irregularities; Roger Bendelac appointed CEO

## Summary
- Lynn Stockwell resigned as CEO, Executive Chair, and Board member of DMAA and affiliate, effective Feb 28, 2026.
- Resignation followed board request after Sponsor withdrew ~$1.1M from affiliate's account, including ~$566K overpayment and $200K for unrelated expenses; Sponsor cannot repay.
- Roger Bendelac appointed as new CEO; has 30+ years in investment banking/corporate advisory; compensation not yet determined.
- Board removed Ms. Stockwell from all positions on Feb 28, 2026.

## SEC filing metadata
- accession: 0001213900-26-024392
- form_type: 8-K
- ticker: DMAA
- cik: 0002028614
- company_name: Drugs Made In America Acquisition Corp.
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2028614/000121390026024392/0001213900-26-024392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2028614/000121390026024392/ea0280328-8k_drugs.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-024392
- JSON: https://secwatch.observer/filing/0001213900-26-024392.json
- Plain text: https://secwatch.observer/filing/0001213900-26-024392.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.